The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Crisomet     6-(2,3-dichlorophenyl)-1,2,4- triazine-3,5...

Synonyms: Labileno, Lamictal, Lamictin, Lamiktal, Lamitor, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of lamotrigine


Psychiatry related information on lamotrigine


High impact information on lamotrigine


Chemical compound and disease context of lamotrigine


Biological context of lamotrigine

  • The pharmacokinetics of lamotrigine, a new anticonvulsant, were studied in three studies in normal volunteers [20].
  • In a second study 10 subjects received 120 mg lamotrigine and the mean (+/- SD) of the elimination half-life (t1/2) was 24.1 +/- 5.7 hours and of volume of distribution/bioavailability 1.2 +/- 0.12 L/kg [20].
  • After dose adjustment of lamotrigine to 200 mg twice daily, the AUC on day 31 (n = 15) was bioequivalent to that on day 10, with a point estimate of 0.91 (90% confidence interval, 0.82-1.02) [21].
  • Carbamazepine, oxcarbazepine, and lamotrigine also inhibited electrically stimulated release of [3H]-5-hydroxytryptamine (IC50 values, 150 to 250 microM) and [3H]-acetylcholine (IC50 values, 50 to 150 microM); [3H]-noradrenaline release was affected to a lesser degree [22].
  • Lamotrigine at 50 mg/kg i.v. for 10 minutes was not cerebroprotective and induced a decrease of 29 +/- 15 mm Hg in mean arterial blood pressure (P < .05, n = 8) [23].

Anatomical context of lamotrigine


Associations of lamotrigine with other chemical compounds


Gene context of lamotrigine


Analytical, diagnostic and therapeutic context of lamotrigine


  1. Lamotrigine for generalized seizures associated with the Lennox-Gastaut syndrome. Trevathan, E., Mullens, E.L., Manasco, P. N. Engl. J. Med. (1998) [Pubmed]
  2. Lamotrigine for generalised epilepsies. Stewart, J., Hughes, E., Reynolds, E.H. Lancet (1992) [Pubmed]
  3. Lamotrigine and toxic epidermal necrolysis. Wadelius, M., Karlsson, T., Wadelius, C., Rane, A. Lancet (1996) [Pubmed]
  4. Lamotrigine in infantile spasms. Veggiotti, P., Cieuta, C., Rex, E., Dulac, O. Lancet (1994) [Pubmed]
  5. Hyponatraemia associated with lamotrigine in cranial diabetes insipidus. Mewasingh, L., Aylett, S., Kirkham, F., Stanhope, R. Lancet (2000) [Pubmed]
  6. Lamotrigine intoxication provoking status epilepticus in an adult with localization-related epilepsy. Dinnerstein, E., Jobst, B.C., Williamson, P.D. Arch. Neurol. (2007) [Pubmed]
  7. A placebo-controlled 18-month trial of lamotrigine and lithium maintenance treatment in recently manic or hypomanic patients with bipolar I disorder. Bowden, C.L., Calabrese, J.R., Sachs, G., Yatham, L.N., Asghar, S.A., Hompland, M., Montgomery, P., Earl, N., Smoot, T.M., DeVeaugh-Geiss, J. Arch. Gen. Psychiatry (2003) [Pubmed]
  8. Aggression in dementia with lamotrigine treatment. Devarajan, S., Dursun, S.M. The American journal of psychiatry. (2000) [Pubmed]
  9. Hallucinations during lamotrigine treatment of bipolar disorder. Uher, R., Jones, H.M. The American journal of psychiatry. (2006) [Pubmed]
  10. A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Hertzberg, M.A., Butterfield, M.I., Feldman, M.E., Beckham, J.C., Sutherland, S.M., Connor, K.M., Davidson, J.R. Biol. Psychiatry (1999) [Pubmed]
  11. Effect of anticonvulsants on nocturnal sleep in epilepsy. Placidi, F., Diomedi, M., Scalise, A., Marciani, M.G., Romigi, A., Gigli, G.L. Neurology (2000) [Pubmed]
  12. Pharmacological upregulation of h-channels reduces the excitability of pyramidal neuron dendrites. Poolos, N.P., Migliore, M., Johnston, D. Nat. Neurosci. (2002) [Pubmed]
  13. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. Rzany, B., Correia, O., Kelly, J.P., Naldi, L., Auquier, A., Stern, R. Lancet (1999) [Pubmed]
  14. Loss of aura in lamotrigine-treated epilepsy. Deleu, D., Hanssens, Y. Lancet (1997) [Pubmed]
  15. Impact of lamotrigine and lithium on weight in obese and nonobese patients with bipolar I disorder. Bowden, C.L., Calabrese, J.R., Ketter, T.A., Sachs, G.S., White, R.L., Thompson, T.R. The American journal of psychiatry. (2006) [Pubmed]
  16. Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidone. Nierenberg, A.A., Ostacher, M.J., Calabrese, J.R., Ketter, T.A., Marangell, L.B., Miklowitz, D.J., Miyahara, S., Bauer, M.S., Thase, M.E., Wisniewski, S.R., Sachs, G.S. The American journal of psychiatry. (2006) [Pubmed]
  17. Multiorgan dysfunction and disseminated intravascular coagulation in children receiving lamotrigine and valproic acid. Chattergoon, D.S., McGuigan, M.A., Koren, G., Hwang, P., Ito, S. Neurology (1997) [Pubmed]
  18. Valproate is associated with new-onset oligoamenorrhea with hyperandrogenism in women with bipolar disorder. Joffe, H., Cohen, L.S., Suppes, T., McLaughlin, W.L., Lavori, P., Adams, J.M., Hwang, C.H., Hall, J.E., Sachs, G.S. Biol. Psychiatry (2006) [Pubmed]
  19. The role of glutamate in epilepsy and other CNS disorders. Meldrum, B.S. Neurology (1994) [Pubmed]
  20. Lamotrigine, a new anticonvulsant: pharmacokinetics in normal humans. Cohen, A.F., Land, G.S., Breimer, D.D., Yuen, W.C., Winton, C., Peck, A.W. Clin. Pharmacol. Ther. (1987) [Pubmed]
  21. Lopinavir/ritonavir reduces lamotrigine plasma concentrations in healthy subjects. van der Lee, M.J., Dawood, L., ter Hofstede, H.J., de Graaff-Teulen, M.J., van Ewijk-Beneken Kolmer, E.W., Caliskan-Yassen, N., Koopmans, P.P., Burger, D.M. Clin. Pharmacol. Ther. (2006) [Pubmed]
  22. Similar potency of carbamazepine, oxcarbazepine, and lamotrigine in inhibiting the release of glutamate and other neurotransmitters. Waldmeier, P.C., Baumann, P.A., Wicki, P., Feldtrauer, J.J., Stierlin, C., Schmutz, M. Neurology (1995) [Pubmed]
  23. Cerebroprotective effect of lamotrigine after focal ischemia in rats. Smith, S.E., Meldrum, B.S. Stroke (1995) [Pubmed]
  24. Tissue-specific, inducible, and hormonal control of the human UDP-glucuronosyltransferase-1 (UGT1) locus. Chen, S., Beaton, D., Nguyen, N., Senekeo-Effenberger, K., Brace-Sinnokrak, E., Argikar, U., Remmel, R.P., Trottier, J., Barbier, O., Ritter, J.K., Tukey, R.H. J. Biol. Chem. (2005) [Pubmed]
  25. Neuroprotective properties of the novel antiepileptic lamotrigine in a gerbil model of global cerebral ischemia. Wiard, R.P., Dickerson, M.C., Beek, O., Norton, R., Cooper, B.R. Stroke (1995) [Pubmed]
  26. Characterization of drug-specific T cells in lamotrigine hypersensitivity. Naisbitt, D.J., Farrell, J., Wong, G., Depta, J.P., Dodd, C.C., Hopkins, J.E., Gibney, C.A., Chadwick, D.W., Pichler, W.J., Pirmohamed, M., Park, B.K. J. Allergy Clin. Immunol. (2003) [Pubmed]
  27. A novel drug binding site on voltage-gated sodium channels in rat brain. Riddall, D.R., Leach, M.J., Garthwaite, J. Mol. Pharmacol. (2006) [Pubmed]
  28. Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings. Upton, N. Trends Pharmacol. Sci. (1994) [Pubmed]
  29. Bone mass and turnover in women with epilepsy on antiepileptic drug monotherapy. Pack, A.M., Morrell, M.J., Marcus, R., Holloway, L., Flaster, E., Doñe, S., Randall, A., Seale, C., Shane, E. Ann. Neurol. (2005) [Pubmed]
  30. Clinical pharmacokinetics of new antiepileptic drugs. Walker, M.C., Patsalos, P.N. Pharmacol. Ther. (1995) [Pubmed]
  31. Disruption of prepulse inhibition in mice lacking mGluR1. Brody, S.A., Conquet, F., Geyer, M.A. Eur. J. Neurosci. (2003) [Pubmed]
  32. The current understanding of lamotrigine as a mood stabilizer. Hahn, C.G., Gyulai, L., Baldassano, C.F., Lenox, R.H. The Journal of clinical psychiatry. (2004) [Pubmed]
  33. Comparison of brain extracellular fluid, brain tissue, cerebrospinal fluid, and serum concentrations of antiepileptic drugs measured intraoperatively in patients with intractable epilepsy. Rambeck, B., Jürgens, U.H., May, T.W., Pannek, H.W., Behne, F., Ebner, A., Gorji, A., Straub, H., Speckmann, E.J., Pohlmann-Eden, B., Löscher, W. Epilepsia (2006) [Pubmed]
  34. Lamotrigine inhibits basal and Na(+)-stimulated, but not Ca (2+)-stimulated, release of corticotropin-releasing hormone from the rat hypothalamus. Tringali, G., Aubry, J.M., Navarra, P., Pozzoli, G. Psychopharmacology (Berl.) (2006) [Pubmed]
  35. Spectrum of activity of lamotrigine in treatment-refractory bipolar disorder. Calabrese, J.R., Bowden, C.L., McElroy, S.L., Cookson, J., Andersen, J., Keck, P.E., Rhodes, L., Bolden-Watson, C., Zhou, J., Ascher, J.A. The American journal of psychiatry. (1999) [Pubmed]
  36. Differential cognitive and behavioral effects of carbamazepine and lamotrigine. Meador, K.J., Loring, D.W., Ray, P.G., Murro, A.M., King, D.W., Perrine, K.R., Vazquez, B.R., Kiolbasa, T. Neurology (2001) [Pubmed]
  37. Lamotrigine reduces painful diabetic neuropathy: a randomized, controlled study. Eisenberg, E., Lurie, Y., Braker, C., Daoud, D., Ishay, A. Neurology (2001) [Pubmed]
  38. A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Stahl, S.M., Grady, M.M. Current medicinal chemistry. (2004) [Pubmed]
WikiGenes - Universities